Literature DB >> 25257923

Site and mechanism of morphine tolerance in the gastrointestinal tract.

H I Akbarali1, A Inkisar, W L Dewey.   

Abstract

Opioid-induced constipation is a major clinical problem. The effects of morphine, and other narcotics, on the gastrointestinal tract persist over long-term use thus limiting the clinical benefit of these excellent pain relievers. The effects of opioids in the gut, including morphine, are largely mediated by the μ-opioid receptors at the soma and nerve terminals of enteric neurons. Recent studies demonstrate that regional differences exist in both acute and chronic morphine along the gastrointestinal tract. While tolerance develops to the analgesic effects and upper gastrointestinal motility upon repeated morphine administration, tolerance does not develop in the colon with chronic opioids resulting in persistent constipation. Here, we review the mechanisms by which tolerance develops in the small but not the large intestine. The regional differences lie in the signaling and regulation of the μ-opioid receptor in the various segments of the gastrointestinal tract. The differential role of β-arrestin2 in tolerance development between central and enteric neurons defines the potential for therapeutic approaches in developing ligands with analgesic properties and minimal constipating effects.
© 2014 John Wiley & Sons Ltd.

Entities:  

Keywords:  beta-arrestin; constipation; opioid; tolerance

Mesh:

Substances:

Year:  2014        PMID: 25257923      PMCID: PMC4423201          DOI: 10.1111/nmo.12443

Source DB:  PubMed          Journal:  Neurogastroenterol Motil        ISSN: 1350-1925            Impact factor:   3.598


  54 in total

1.  Identification and characterization of six new alternatively spliced variants of the human mu opioid receptor gene, Oprm.

Authors:  L Pan; J Xu; R Yu; M-M Xu; Y-X Pan; G W Pasternak
Journal:  Neuroscience       Date:  2005       Impact factor: 3.590

Review 2.  Functional selectivity at the μ-opioid receptor: implications for understanding opioid analgesia and tolerance.

Authors:  Kirsten M Raehal; Cullen L Schmid; Chad E Groer; Laura M Bohn
Journal:  Pharmacol Rev       Date:  2011-08-26       Impact factor: 25.468

3.  Enhanced morphine analgesia in mice lacking beta-arrestin 2.

Authors:  L M Bohn; R J Lefkowitz; R R Gainetdinov; K Peppel; M G Caron; F T Lin
Journal:  Science       Date:  1999-12-24       Impact factor: 47.728

4.  The role of β-arrestin2 in the mechanism of morphine tolerance in the mouse and guinea pig gastrointestinal tract.

Authors:  Minho Kang; Hercules T Maguma; Tricia H Smith; Gracious R Ross; William L Dewey; Hamid I Akbarali
Journal:  J Pharmacol Exp Ther       Date:  2011-11-30       Impact factor: 4.030

5.  Morphine side effects in beta-arrestin 2 knockout mice.

Authors:  Kirsten M Raehal; Julia K L Walker; Laura M Bohn
Journal:  J Pharmacol Exp Ther       Date:  2005-05-25       Impact factor: 4.030

6.  Differential development of acute tolerance to analgesia, respiratory depression, gastrointestinal transit and hormone release in a morphine infusion model.

Authors:  G S Ling; D Paul; R Simantov; G W Pasternak
Journal:  Life Sci       Date:  1989       Impact factor: 5.037

Review 7.  Alvimopan for postoperative ileus.

Authors:  Heather R Bream-Rouwenhorst; Matthew A Cantrell
Journal:  Am J Health Syst Pharm       Date:  2009-07-15       Impact factor: 2.637

8.  Morphine tolerance in the mouse ileum and colon.

Authors:  Gracious R Ross; Bichoy H Gabra; William L Dewey; Hamid I Akbarali
Journal:  J Pharmacol Exp Ther       Date:  2008-08-05       Impact factor: 4.030

9.  Suppression of inhibitory neural input to colonic circular muscle by opioid peptides.

Authors:  J R Grider; G M Makhlouf
Journal:  J Pharmacol Exp Ther       Date:  1987-10       Impact factor: 4.030

10.  Morphine decreases enteric neuron excitability via inhibition of sodium channels.

Authors:  Tricia H Smith; John R Grider; William L Dewey; Hamid I Akbarali
Journal:  PLoS One       Date:  2012-09-21       Impact factor: 3.240

View more
  21 in total

1.  Effects of acute and repeated treatment with the biased mu opioid receptor agonist TRV130 (oliceridine) on measures of antinociception, gastrointestinal function, and abuse liability in rodents.

Authors:  Ahmad A Altarifi; Bethany David; Karan H Muchhala; Bruce E Blough; Hamid Akbarali; S Stevens Negus
Journal:  J Psychopharmacol       Date:  2017-02-01       Impact factor: 4.153

Review 2.  The gut-brain interaction in opioid tolerance.

Authors:  Hamid I Akbarali; William L Dewey
Journal:  Curr Opin Pharmacol       Date:  2017-11-13       Impact factor: 5.547

Review 3.  Opioid-induced constipation: advances and clinical guidance.

Authors:  Alfred D Nelson; Michael Camilleri
Journal:  Ther Adv Chronic Dis       Date:  2016-01-25       Impact factor: 5.091

Review 4.  Loperamide cardiotoxicity: "A Brief Review".

Authors:  Tamer Akel; Soad Bekheit
Journal:  Ann Noninvasive Electrocardiol       Date:  2017-11-10       Impact factor: 1.468

Review 5.  Targeting Small Bowel Receptors to Treat Constipation and Diarrhea.

Authors:  Elizabeth S John; Sita Chokhavatia
Journal:  Curr Gastroenterol Rep       Date:  2017-07

Review 6.  Chronic opioid induced constipation in patients with nonmalignant pain: challenges and opportunities.

Authors:  Alfred D Nelson; Michael Camilleri
Journal:  Therap Adv Gastroenterol       Date:  2015-07       Impact factor: 4.409

7.  Evidence for Modulation of Substance Use Disorders by the Gut Microbiome: Hidden in Plain Sight.

Authors:  Mariana Angoa-Pérez; Donald M Kuhn
Journal:  Pharmacol Rev       Date:  2021-04       Impact factor: 25.468

8.  6β-N-Heterocyclic Substituted Naltrexamine Derivative BNAP: A Peripherally Selective Mixed MOR/KOR Ligand.

Authors:  Dwight A Williams; Yi Zheng; Bethany G David; Yunyun Yuan; Saheem A Zaidi; David L Stevens; Krista L Scoggins; Dana E Selley; William L Dewey; Hamid I Akbarali; Yan Zhang
Journal:  ACS Chem Neurosci       Date:  2016-06-15       Impact factor: 4.418

9.  Methylation Products of 6β- N-Heterocyclic Substituted Naltrexamine Derivatives as Potential Peripheral Opioid Receptor Modulators.

Authors:  Yi Zheng; Samuel Obeng; Huiqun Wang; David L Stevens; Essie Komla; Dana E Selley; William L Dewey; Hamid I Akbarali; Yan Zhang
Journal:  ACS Chem Neurosci       Date:  2018-07-23       Impact factor: 4.418

Review 10.  Medications Development for Treatment of Opioid Use Disorder.

Authors:  E Andrew Townsend; S Stevens Negus; Matthew L Banks
Journal:  Cold Spring Harb Perspect Med       Date:  2021-01-04       Impact factor: 6.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.